VLX600 is primarily used in research settings as a metabolic inhibitor targeting cancer cell energy pathways. It has shown potential in studies focused on tumor microenvironment modulation, particularly in hypoxic and nutrient-deprived conditions where cancer cells rely on alternative metabolic processes. By disrupting mitochondrial function and reducing cellular energy production, VLX600 can selectively impair the survival of dormant or slow-cycling tumor cells that are often resistant to conventional therapies. This makes it a valuable tool compound in oncology research, especially in developing strategies to eliminate residual disease and prevent cancer recurrence. Its application is currently limited to preclinical studies and is not used in clinical treatment.